Furthermore, TEM results showed that HS20 pre-treatment abolished the effect of TFPI on TEM (p = 0.0074), although HS20 itself has no significant effect on the migration of CLL cells (p = 0.5) (Fig. 4G). The gene discussed is TFPI; the disease is B-cell chronic lymphocytic leukemia.